Results 81 to 90 of about 54,283 (258)
Therapeutic Options for Visceral Leishmaniasis [PDF]
Drugs, 2013 Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of ...
Begoña Monge-Maillo +1 more
openaire +3 more sources
The recombinant cysteine proteinase B (CPB) from Leishmania braziliensis and its domains: promising antigens for serodiagnosis of cutaneous and visceral leishmaniasis in dogs. [PDF]
, 2019 Leishmaniasis represents a group of parasitic diseases caused by a protozoan of the genus Leishmania and is widely distributed in tropical and subtropical regions.
Basombrío, Manuel Alberto +10 more
core +1 more source
A case of visceral leishmaniasis mimicking connective tissue disease
Rheumatology &Autoimmunity, EarlyView.
Yucui Li +4 more
wiley +1 more source
Small, Volume 21, Issue 29, July 24, 2025.This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai +5 more
wiley +1 more source
Interventions for visceral leishmaniasis
Cochrane Database of Systematic Reviews, 2010 Reason for withdrawal from publication This protocol is being withdrawn from The Cochrane Library. The authors have made no progress with this protocol in seven years. The protocol is out of date and does not meet the current methodological standards of Cochrane.
Urbà González +6 more
openaire +3 more sources
Experimental Dermatology, Volume 34, Issue 7, July 2025.ABSTRACT Treatment against leishmaniasis is associated with severe side effects, high costs, and parasitic resistance. Preclinical models such as humanised mice would aid therapeutic improvement or the development of a vaccine. We developed a model in which human skin transplants on immunodeficient mice are infected with Leishmania major.
Ling Miao +4 more
wiley +1 more source
Parasite Immunology, Volume 47, Issue 7, July 2025.ABSTRACT Kala‐azar, or visceral leishmaniasis (VL), is a parasitic disease caused by Leishmania spp., characterised by fever, weight loss, splenomegaly, hepatomegaly, and anaemia. This study evaluated the relationship between hepcidin, inflammation, iron metabolism, and hypersplenism in VL‐associated anaemia. In this cross‐sectional study, confirmed VL
Alyne Ferreira De Almendra Freitas +8 more
wiley +1 more source
Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum. [PDF]
, 2002 One explanation proposed for the widespread failure to control zoonotic visceral leishmaniasis by culling infected domestic dogs is that wild canids or humans play significant roles in transmission.
Davies, Clive R +4 more
core +1 more source
Public Health Challenges, Volume 4, Issue 2, June 2025.An update on the composition and distribution of sand fly species in the Nile environments of Khartoum. Variations were observed in species number than in species composition. The study will be a good reference for future studies on sandflies after the change in their habitat due to the current war in Sudan. ABSTRACT Phlebotomine sand flies are vectors
Suhaib A. Gumaa +3 more
wiley +1 more source